Medical Biotechnology: Grafts, Patents, and Clinical Trial Phases

Organ and Tissue Transplantation: Grafts and Rejection

Transplantation is the process of implanting organs or tissue. The transplanted material is commonly referred to as a Graft.

Understanding Graft Rejection

Rejection occurs when the recipient's immune system attacks the transplanted tissue, sometimes immediately after the operation. To prevent this, compatibility between the donor and recipient must be thoroughly checked.

Immunodepressors (or immunosuppressants) are medications that cause a decrease in the activity of the body's defense system, thereby minimizing the risk of rejection.

Types of Transplantation

• Autotransplantation: This is the re-implantation of tissue within the same individual, moving a healthy part to replace a damaged one (e.g., skin grafts).
• Isotransplantation: Transplantation performed between genetically identical individuals, as in the case of identical (univitel) twins.
• Allotransplantation (Allograft): Transplantation performed between members of the same species but with different genetic constitutions (the most common type of human-to-human transplant).
• Xenotransplantation: Transplantation performed between individuals of different species, such as using pig heart valves or skin grafts in humans.

Legal and Ethical Aspects of Organ Donation

Organ donation requires the gift-giving individual or their family to have expressed consent for the donation. Spanish law requires that the donor's family does not charge for the donation. Transplanted patients are protected by anonymity and do not pay for the transplant procedure itself.

Pharmaceutical Innovation and Regulation

Patents and Generic Medicines

A Patent is the title given by the state. It grants the owner a monopoly in the industrial and commercial exploitation of the patented invention for a specific period of time.

Generic Medicines are developed and manufactured in accordance with current regulations. They have the same qualitative and quantitative composition as the reference drug and are also bioequivalent to it.

Clinical Trial Phases for Drug Development

The development of a new medicine involves rigorous testing through four distinct clinical trial phases:

1. First Phase: Safety and Dosage

   This phase is done with a small group of healthy volunteers. The goal is to determine the dose that produces a response, how the medicine is processed by the body, and whether the medicine is toxic or causes undesirable effects.

2. Second Phase: Efficacy in Patients

   This phase is done with a selected group of patients with the disease the drug is intended to cure. It aims at determining the potential positive effects and identifying any dangerous side effects.

3. Third Phase (Trial): Comparison and Confirmation

   This phase involves administering the medication to a large number of patients. The results are compared, if applicable, with other already used treatments or a placebo.

4. Fourth Phase: Post-Marketing Surveillance

   If satisfactory results are produced, authorization for marketing of the drug is sought. During the early years, controlled monitoring of the drug continues in order to detect possible side effects not collected in previous phases.